


Diflomotecan

Cat. No.:	HY-13611
CAS No.:	220997-97-7
Molecular Formula:	C ₂₁ H ₁₆ F ₂ N ₂ O ₄
Molecular Weight:	398.36
Target:	Topoisomerase
Pathway:	Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Diflomotecan (BN 80915) is a potent and orally active inhibitor of topoisomerase I. Diflomotecan (BN 80915) causes enhanced plasma stability and has the superior preclinical anti-tumour activity compared with other established compounds ^{[1][2]} .
IC ₅₀ & Target	topoisomerase I ^[1]

REFERENCES

[1]. Kroep JR, et al. Diflomotecan, a promising homocamptothecin for cancer therapy. *Expert Opin Investig Drugs*. 2009;18(1):69-75.

[2]. Gelderblom H, et al. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. *Clin Cancer Res*. 2003;9(11):4101-4107.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA